000184029212/312024Q3FALSEhttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrentxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pure00018402922024-01-012024-09-300001840292us-gaap:CommonStockMember2024-01-012024-09-300001840292us-gaap:WarrantMember2024-01-012024-09-300001840292hlg:PreferredSharePurchaseRightMember2024-01-012024-09-3000018402922024-11-0400018402922024-09-3000018402922023-12-3100018402922024-07-012024-09-3000018402922023-07-012023-09-3000018402922023-01-012023-09-300001840292us-gaap:CommonStockMember2024-06-300001840292us-gaap:AdditionalPaidInCapitalMember2024-06-300001840292us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001840292us-gaap:RetainedEarningsMember2024-06-3000018402922024-06-300001840292us-gaap:RetainedEarningsMember2024-07-012024-09-300001840292us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001840292us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001840292us-gaap:CommonStockMember2024-07-012024-09-300001840292us-gaap:AdditionalPaidInCapitalMemberhlg:CustomerAgreementsMember2024-07-012024-09-300001840292hlg:CustomerAgreementsMember2024-07-012024-09-300001840292us-gaap:CommonStockMember2024-09-300001840292us-gaap:AdditionalPaidInCapitalMember2024-09-300001840292us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001840292us-gaap:RetainedEarningsMember2024-09-300001840292us-gaap:CommonStockMember2023-06-300001840292us-gaap:AdditionalPaidInCapitalMember2023-06-300001840292us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001840292us-gaap:RetainedEarningsMember2023-06-3000018402922023-06-300001840292us-gaap:RetainedEarningsMember2023-07-012023-09-300001840292us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001840292us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001840292us-gaap:CommonStockMember2023-07-012023-09-300001840292us-gaap:AdditionalPaidInCapitalMemberhlg:CustomerAgreementsMember2023-07-012023-09-300001840292hlg:CustomerAgreementsMember2023-07-012023-09-300001840292us-gaap:CommonStockMember2023-09-300001840292us-gaap:AdditionalPaidInCapitalMember2023-09-300001840292us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001840292us-gaap:RetainedEarningsMember2023-09-3000018402922023-09-300001840292us-gaap:CommonStockMember2023-12-310001840292us-gaap:AdditionalPaidInCapitalMember2023-12-310001840292us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001840292us-gaap:RetainedEarningsMember2023-12-310001840292us-gaap:RetainedEarningsMember2024-01-012024-09-300001840292us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001840292us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001840292us-gaap:CommonStockMember2024-01-012024-09-300001840292us-gaap:AdditionalPaidInCapitalMemberhlg:CustomerAgreementsMember2024-01-012024-09-300001840292hlg:CustomerAgreementsMember2024-01-012024-09-300001840292us-gaap:CommonStockMember2022-12-310001840292us-gaap:AdditionalPaidInCapitalMember2022-12-310001840292us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001840292us-gaap:RetainedEarningsMember2022-12-3100018402922022-12-310001840292us-gaap:RetainedEarningsMember2023-01-012023-09-300001840292us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001840292us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001840292us-gaap:CommonStockMember2023-01-012023-09-300001840292us-gaap:AdditionalPaidInCapitalMemberhlg:CustomerAgreementsMember2023-01-012023-09-300001840292hlg:CustomerAgreementsMember2023-01-012023-09-300001840292hlg:ProjectRevenueMember2024-07-012024-09-300001840292hlg:ProjectRevenueMember2023-07-012023-09-300001840292hlg:ProjectRevenueMember2024-01-012024-09-300001840292hlg:ProjectRevenueMember2023-01-012023-09-300001840292us-gaap:ServiceMember2024-07-012024-09-300001840292us-gaap:ServiceMember2023-07-012023-09-300001840292us-gaap:ServiceMember2024-01-012024-09-300001840292us-gaap:ServiceMember2023-01-012023-09-300001840292us-gaap:BilledRevenuesMember2024-09-300001840292us-gaap:BilledRevenuesMember2023-12-310001840292us-gaap:UnbilledRevenuesMember2024-09-300001840292us-gaap:UnbilledRevenuesMember2023-12-310001840292hlg:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-07-012024-09-300001840292hlg:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2023-07-012023-09-300001840292hlg:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-01-012024-09-300001840292hlg:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2023-01-012023-09-300001840292hlg:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-07-012024-09-300001840292hlg:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2023-07-012023-09-300001840292hlg:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-01-012024-09-300001840292hlg:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2023-01-012023-09-300001840292hlg:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-09-300001840292hlg:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310001840292hlg:CustomerCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-09-300001840292hlg:CustomerCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310001840292hlg:PublicWarrantsMember2024-09-300001840292hlg:PrivateWarrantsMember2024-09-300001840292hlg:PublicAndPrivateWarrantsMember2024-09-300001840292hlg:ProjectWarrantsMember2022-03-310001840292hlg:ProjectWarrantsMember2024-07-012024-09-300001840292hlg:ProjectWarrantsMember2024-01-012024-09-300001840292hlg:ProjectWarrantsMember2023-07-012023-09-300001840292hlg:ProjectWarrantsMember2023-01-012023-09-300001840292hlg:ProjectWarrantsMemberhlg:WarrantVestedMember2024-09-300001840292hlg:CollaborationWarrantsMember2022-03-310001840292hlg:CollaborationWarrantsMemberhlg:WarrantVestingImmediatelyMember2022-03-310001840292hlg:CollaborationWarrantsMember2023-07-012023-09-300001840292hlg:CollaborationWarrantsMember2023-01-012023-09-300001840292us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001840292us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001840292hlg:PublicWarrantsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001840292hlg:PublicWarrantsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001840292hlg:PrivateWarrantsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001840292hlg:PrivateWarrantsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001840292us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001840292us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001840292us-gaap:FairValueInputsLevel3Member2023-06-300001840292us-gaap:FairValueInputsLevel3Member2022-12-310001840292us-gaap:FairValueInputsLevel3Member2023-07-012023-09-300001840292us-gaap:FairValueInputsLevel3Member2023-01-012023-09-300001840292us-gaap:FairValueInputsLevel3Member2023-09-300001840292srt:MinimumMemberus-gaap:LeaseholdImprovementsMember2024-09-300001840292srt:MaximumMemberus-gaap:LeaseholdImprovementsMember2024-09-300001840292us-gaap:LeaseholdImprovementsMember2024-09-300001840292us-gaap:LeaseholdImprovementsMember2023-12-310001840292srt:MinimumMemberus-gaap:ComputerEquipmentMember2024-09-300001840292srt:MaximumMemberus-gaap:ComputerEquipmentMember2024-09-300001840292us-gaap:ComputerEquipmentMember2024-09-300001840292us-gaap:ComputerEquipmentMember2023-12-310001840292srt:MinimumMemberhlg:MachineryVehiclesAndOtherEquipmentMember2024-09-300001840292srt:MaximumMemberhlg:MachineryVehiclesAndOtherEquipmentMember2024-09-300001840292hlg:MachineryVehiclesAndOtherEquipmentMember2024-09-300001840292hlg:MachineryVehiclesAndOtherEquipmentMember2023-12-310001840292srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2024-09-300001840292srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2024-09-300001840292us-gaap:FurnitureAndFixturesMember2024-09-300001840292us-gaap:FurnitureAndFixturesMember2023-12-310001840292us-gaap:ConstructionInProgressMember2024-09-300001840292us-gaap:ConstructionInProgressMember2023-12-3100018402922024-04-012024-06-300001840292hlg:ManufacturingSpaceInLongBeachCaliforniaMemberus-gaap:StandbyLettersOfCreditMemberus-gaap:LineOfCreditMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2024-09-3000018402922023-04-160001840292hlg:PreferredSharePurchaseRightMember2023-04-1600018402922024-04-160001840292hlg:PreferredSharePurchaseRightMember2024-04-160001840292us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001840292us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001840292us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001840292us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001840292us-gaap:EmployeeStockMember2024-07-012024-09-300001840292us-gaap:EmployeeStockMember2023-07-012023-09-300001840292us-gaap:EmployeeStockMember2024-01-012024-09-300001840292us-gaap:EmployeeStockMember2023-01-012023-09-300001840292us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001840292us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001840292us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001840292us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001840292hlg:UnvestedWarrantsMemberus-gaap:WarrantMember2024-07-012024-09-300001840292hlg:UnvestedWarrantsMemberus-gaap:WarrantMember2023-07-012023-09-300001840292hlg:UnvestedWarrantsMemberus-gaap:WarrantMember2024-01-012024-09-300001840292hlg:UnvestedWarrantsMemberus-gaap:WarrantMember2023-01-012023-09-300001840292hlg:CommonStockWarrantsMemberus-gaap:WarrantMember2024-07-012024-09-300001840292hlg:CommonStockWarrantsMemberus-gaap:WarrantMember2023-07-012023-09-300001840292hlg:CommonStockWarrantsMemberus-gaap:WarrantMember2024-01-012024-09-300001840292hlg:CommonStockWarrantsMemberus-gaap:WarrantMember2023-01-012023-09-300001840292us-gaap:CostOfSalesMember2024-07-012024-09-300001840292us-gaap:CostOfSalesMember2023-07-012023-09-300001840292us-gaap:CostOfSalesMember2024-01-012024-09-300001840292us-gaap:CostOfSalesMember2023-01-012023-09-300001840292us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300001840292us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001840292us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300001840292us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001840292us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001840292us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001840292us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001840292us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001840292us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001840292us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001840292us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001840292us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001840292us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001840292us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001840292us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001840292us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001840292us-gaap:EmployeeStockMember2024-07-012024-09-300001840292us-gaap:EmployeeStockMember2023-07-012023-09-300001840292us-gaap:EmployeeStockMember2024-01-012024-09-300001840292us-gaap:EmployeeStockMember2023-01-012023-09-300001840292hlg:VendorWarrantsMember2024-07-012024-09-300001840292hlg:VendorWarrantsMember2023-07-012023-09-300001840292hlg:VendorWarrantsMember2024-01-012024-09-300001840292hlg:VendorWarrantsMember2023-01-012023-09-300001840292us-gaap:EmployeeStockOptionMember2023-12-310001840292us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001840292us-gaap:EmployeeStockOptionMember2024-09-300001840292us-gaap:RestrictedStockUnitsRSUMember2023-12-310001840292us-gaap:RestrictedStockUnitsRSUMember2024-09-300001840292us-gaap:FacilityClosingMembersrt:MinimumMembersrt:ScenarioForecastMember2024-12-310001840292us-gaap:FacilityClosingMembersrt:MaximumMembersrt:ScenarioForecastMember2024-12-3100018402922023-01-012023-03-310001840292us-gaap:SubsequentEventMember2024-10-012024-10-310001840292us-gaap:RelatedPartyMemberhlg:NantGPowerLLCMember2024-07-012024-09-300001840292us-gaap:RelatedPartyMemberhlg:NantGPowerLLCMember2024-01-012024-09-300001840292us-gaap:RelatedPartyMemberhlg:NantGPowerLLCMember2023-01-012023-09-300001840292us-gaap:RelatedPartyMemberhlg:NantGPowerLLCMember2023-07-012023-09-300001840292us-gaap:RelatedPartyMemberhlg:NantGPowerLLCMember2024-09-300001840292us-gaap:RelatedPartyMemberhlg:NantGPowerLLCMember2023-12-31
目录
美国
证券交易委员会
华盛顿特区20549
表格 10-Q
x根据1934年《证券交易法》第13条或第15(d)条提交的季度报告
截至季度结束日期的财务报告2024年9月30日
or
o根据1934年证券交易法第13或15(d)节的转型报告书
过渡期从______________到______________
委托文件编号:001-39866001-40209
Heliogen,公司。
(根据其章程规定的注册人准确名称)
特拉华州85-4204953
(设立或组织的其他管辖区域)(纳税人识别号码)
西联街130号, 帕萨迪纳市, 加利福尼亚州
91103
(主要领导机构的地址)(邮政编码)
注册人的电话号码,包括区号:(626) 720-4530
在法案第12(b)条的规定下注册的证券:
每一类的名称交易标志在其上注册的交易所的名称
solana交易所HLGNOTCQX
每35份权证,可行使换购一股普通股,行使价格为每股402.50美元
HLGNW
OTCPK
优先股购买权N/AOTCQX
请在检查标记处表示登记者:(1)已按证券交易法的13或15(d)条规定提交所有报告,涵盖过去12个月(或较短时期内要求登记者提交该等报告的时间);和(2)过去90天一直存在报告要求。Yes xo
请勾选方框,以表明注册人是否在过去12个月内(或其要求提交此类文件的较短期限内)提交了每份交互式数据文件,其提交是根据规则405号第S-T条(本章第232.405条)要求提交的。Yes xo
请在以下选项前打勾表示公司属于大型快速记录者、快速记录者、非快速记录者、小额报告公司还是新兴增长公司。可参考《交易所法规》规则12亿.2中对“大型快速记录者”、“快速记录者”、“小额报告公司”和“新兴增长公司”的定义。
大型加速报告人o加速文件提交人o
非加速文件提交人x较小的报告公司x
新兴成长公司x
如果是新兴成长型企业,请勾选复选标记,表明注册者已选择不使用延长过渡期来符合根据证券交易法第13(a)条规定提供的任何新财务会计准则。 x
勾选表示注册人是否为无实质业务的公司(根据法规12b-2条规定)。 是ox
截至2024年11月4日,注册人持有 6,049,012 股普通股,每股面值0.0001美元。


目录
目录
页面
第一部分 -财务信息
第二部分 -其他信息

2

目录
关于前瞻性声明的警示说明
本季度报告表格10-Q(以下简称“季度报告”)包含根据1933年修订版证券法(以下简称“证券法”)第27A条和1934年修订版证券交易所法(以下简称“交易所法”)第21E条的意义而进行的前瞻性陈述。我们基于我们对未来事件的当前期望和预测,做出了这些前瞻性陈述。本季度报告中包含的所有声明,除了关于我们未来财务业绩,以及我们的策略、未来业务、财务状况、预估收入、损失、预计成本、前景、计划和管理目标的陈述之外,都属于前瞻性陈述。任何涉及对未来事件或情况的投影、预测或其他描述,包括任何基本假设的陈述,都属于前瞻性陈述。在某些情况下,您可以通过类似“预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“预测”、“意图”、“可能”、“潜在”、“预测”、“规划”、“可能”、“潜在”、“预测”、“预测”、“规划”、“目标”、“将”、“将”或类似词汇识别出前瞻性陈述等术语。这些前瞻性陈述是基于管理层对未来事件的当前期望、假设、希望、信念、意图和策略,并根据当前可获得的关于未来事件结果和时间安排的信息而做出的。虽然我们认为这些期望和假设是合理的,但它们本质上是不确定的,并涉及一系列超出我们控制范围的风险和不确定性。此外,管理层对未来事件的假设可能被证明是不准确的。我们提醒读者注意,本季度报告中包含的前瞻性陈述并非未来业绩的保证,我们不能保证任何读者这些陈述将会实现或前瞻事件和情况将会发生。
由于许多已知和未知的风险和不确定性的影响,我们的实际结果或表现可能与这些前瞻性声明所表示或暗示的结果存在实质性差异。导致实际结果不同的一些因素包括:
我们有能力为未来的现金义务提供资金,并继续作为一个持续经营的机构;
我们能够获取资金来源,以资助我们的运营和未来的资本需求;
我们的财务和业务表现,包括财务预测和业务指标中不确定性风险,以及其中的任何基本假设;
我们普通股和公开认股权从纽约证券交易所(“NYSE”)退市,我们的普通股和认股权开始在场外交易市场交易;
业务和策略的变化,未来运营,财务状况,预计收入和损失,预算成本,前景和计划;
我们执行业务模型的能力包括市场对我们计划中的产品和服务的接受程度,以及以可接受的质量水平和价格达到足够的生产量;
国内外业务、市场、金融、政治、法律条件和适用的法律法规的变化;
我们在现有市场或任何我们可能进入的新市场中增加市场份额的能力;
我们在未来实现和保持盈利的能力;
我们维持和提升产品及品牌的能力,以及吸引和留住客户的能力;
我们寻找新合作伙伴以推出产品的能力;
我们与第三方战略关系的成功;
我们以具有成本效益的方式扩展的能力;
与我们的竞争对手和行业相关的发展和预测;
供应链中断;
我们保护知识产权(“IP”)的能力;

3

目录
我们的股东的行为以及其对我们普通股价格的相关影响;
关于我们将在2012年修正的《初创企业刺激法案》下成为新兴增长公司的时间预期;
我们发现和留住关键员工及重要人员的能力;
我们成功管理高管团队变动的能力;
我们可能会受到其他经济、业务和/或竞争因素的不利影响的可能性;
期货交易所和利率期货;
已知和未知诉讼及监管程序的结果;以及
其他风险和不确定因素,包括我们在截至2023年12月31日的年度报告“10-K表格”的第I部分“第1A项 风险因素”中披露的那些风险,已经于2024年3月26日提交给证券交易委员会(“SEC”),并由我们截至2024年3月31日和2024年6月30日的季度报告第II部分第1A项“风险因素”中披露的风险因素进行补充,以及公司在向SEC提交或将要提交的其他文件中包含的风险因素和其他警示性声明。
鉴于这些风险和不确定性,您不应对这些前瞻性陈述过于依赖。如果本季度报告中描述的一项或多项风险或不确定性,或者基础假设被证明不正确,实际结果和计划可能会与任何前瞻性陈述中表达的内容有实质性差异。我们的SEC文件可以在SEC的网站上公开获取。 www.sec.gov.
您应当以这样的理解阅读本季度报告:我们的实际未来结果、活动水平和表现,以及其他事件和情况,可能与我们的预期有重大不同。我们对所有前瞻性声明进行这些警示性说明。

4

目录
第一部分 - 基本报表
项目1. 财务报表
Heliogen, Inc.
合并资产负债表
(以千为单位的$,除了分享数据)
(未经审计)
2024年9月30日2023年12月31日
资产
现金及现金等价物
$44,631 $62,715 
短期受限现金500 500 
投资
 12,386 
应收账款,净额
1,954 4,679 
存货,净额
 1,956 
预付账款及其他流动资产
1,675 1,230 
总流动资产
48,760 83,466 
经营租赁使用权资产
6,166 13,909 
物业、厂房及设备,净值
627 5,577 
长期受限制现金
1,000 1,000 
其他长期资产
1,439 3,081 
总资产
$57,992 $107,033 
负债和股东权益(赤字)
应付贸易款
$1,073 $746 
应计费用和其他流动负债
9,795 8,907 
合同负债
19,818 17,008 
合同损失准备金74,271 75,340 
总流动负债
104,957 102,001 
经营租赁负债,非流动
4,531 12,878 
其他长期负债
96 169 
总负债
109,584 115,048 
承诺和或有事项(注释15)
股东权益(亏损)
优先股,$0.0001 面值; 10,000,000授权股份及 截至2024年9月30日和2023年12月31日的已发行股份
  
普通股,$0.0001 面值; 500,000,000 授权股份; 6,049,0125,946,315 截至2024年9月30日和2023年12月31日,已发行和流通的股份
1 1 
额外实收资本
433,432 430,678 
累计其他综合损失
(525)(516)
累计亏损
(484,500)(438,178)
股东权益(赤字)总额(51,592)(8,015)
总负债和股东权益(赤字)$57,992 $107,033 
所附注释是这些未经审计的合并基本报表的重要组成部分。

5

目录
Heliogen, Inc.
合并运营报表
(单位为千美元,除每股及股份数据外)
(未经审计)
截至三个月截至九个月
九月三十日九月三十日
2024202320242023
营业收入:
服务收入$434 $1,096 $2,174 $2,874 
补助收入616 1,177 2,665 2,730 
总营业收入1,050 2,273 4,839 5,604 
营业成本:
服务收入成本(包括折旧)494 1,220 3,851 3,221 
补助收入成本616 1,177 2,665 2,690 
合同损失(调整)准备金 (538) (148)
总成本费用1,110 1,859 6,516 5,763 
毛利润(亏损)(60)414 (1,677)(159)
营业费用:
销售、一般和行政7,854 14,882 29,714 36,227 
研究和开发4,509 5,162 13,051 15,368 
减值及其他费用202 115 4,362 1,595 
总营业费用12,565 20,159 47,127 53,190 
运营损失(12,625)(19,745)(48,804)(53,349)
净利息收入535 335 1,893 888 
认股权证重新计量收益53 74 74 326 
其他收入,净额223 767 520 1,341 
税前净亏损(11,814)(18,569)(46,317)(50,794)
所得税准备(1)(1)(5)(3)
净损失$(11,815)$(18,570)$(46,322)$(50,797)
每股亏损:
每股损失 - 基本和稀释
$(1.94)$(3.13)$(7.66)$(8.81)
加权平均流通股数 - 基本和稀释
6,086,382 5,935,823 6,051,029 5,765,356 
所附注释是这些未经审计的合并基本报表的重要组成部分。

6

目录
Heliogen, Inc.
综合损失表
(以千美元计)
(未经审计)
截至三个月截至九个月
九月三十日九月三十日
2024202320242023
净损失$(11,815)$(18,570)$(46,322)$(50,797)
其他综合收益(损失),税后净额:
可供出售证券的未实现收益 72 1 270 
累计汇率调整(6)(124)(10)(185)
其他全面收入(损失),税后净额(6)(52)(9)85 
综合损失$(11,821)$(18,622)$(46,331)$(50,712)
所附注释是这些未经审计的合并基本报表的重要组成部分。

7

目录
Heliogen, Inc.
合并股东权益(亏损)报表
(以千为单位的$,除了分享数据)
(未经审计)
截至2024年9月30日的三个月
普通股
额外实收资本
资本
累计其他全面收益亏损
累计
赤字
总计
股份金额
截至2024年6月30日的余额5,989,932 $1 $432,724 $(519)$(472,685)$(40,479)
净损失— — — — (11,815)(11,815)
其他综合损失— — — (6)— (6)
基于股份的薪酬— — 709 — — 709 
限制性股票单位兑现77,139 — — — — — 
与限制性股票单位归属相关的税收扣缴(21,877)— (45)— — (45)
行使股票期权3,818 — 3 — — 3 
与客户协议相关的Warrants归属— — 41 — — 41 
截至2024年9月30日的余额6,049,012 $1 $433,432 $(525)$(484,500)$(51,592)
截至2023年9月30日的三个月
普通股
额外实收资本
资本
累计其他全面收益亏损
累计
赤字
总计
股份金额
截至2023年6月30日的余额5,844,979 $1 $429,581 $(456)$(340,807)$88,319 
净损失— — — — (18,570)(18,570)
其他综合损失— — — (52)— (52)
基于股份的薪酬— — 305 — — 305 
限制性股票单位兑现62,888 — — — — — 
行使股票期权1,652 — 10 — — 10 
与反向拆分相关的碎股付款(795)— (7)— — (7)
与客户协议相关的Warrants归属— — 95 — — 95 
截至2023年9月30日的余额5,908,724 $1 $429,984 $(508)$(359,377)$70,100 
所附注释是这些未经审计的合并基本报表的重要组成部分。

8

目录
Heliogen, Inc.
合并股东权益(亏损)表(续)
(以千为单位的$,除了分享数据)
(未经审计)
Nine Months Ended September 30, 2024
Common Stock
Additional Paid-in
Capital
Accumulated Other Comprehensive Loss
Accumulated
Deficit
Total
SharesAmount
Balance as of December 31, 20235,946,315 $1 $430,678 $(516)$(438,178)$(8,015)
Net loss— — — — (46,322)(46,322)
Other comprehensive loss— — — (9)— (9)
Share-based compensation— — 2,676 — — 2,676 
Issuance of common stock under employee stock purchase plan8,114 — 13 — — 13 
Vesting of restricted stock units129,505 — — — — — 
Tax withholding related to vesting of restricted stock units(38,740)— (73)— — (73)
Exercise of stock options3,818 — 3 — — 3 
Vesting of warrants issued in connection with customer agreements— — 135 — — 135 
Balance as of September 30, 20246,049,012 $1 $433,432 $(525)$(484,500)$(51,592)

Nine Months Ended September 30, 2023
Common Stock
Additional Paid-in
Capital
Accumulated Other Comprehensive Income (Loss)Accumulated
Deficit
Total
SharesAmount
Balance as of December 31, 20225,511,839 $1 $434,496 $(593)$(308,580)$125,324 
Net loss— — — — (50,797)(50,797)
Other comprehensive income— — — 85 — 85 
Share-based compensation— — (6,078)— — (6,078)
Issuance of common stock under employee stock purchase plan19,284 — 168 — — 168 
Vesting of restricted stock units122,524 — — — — — 
Exercise of stock options255,872 — 1,171 — — 1,171 
Payment for fractional shares in connection with the reverse stock split(795)— (7)— — (7)
Vesting of warrants issued in connection with customer agreements— — 234 — — 234 
Balance as of September 30, 20235,908,724 $1 $429,984 $(508)$(359,377)$70,100 
The accompanying notes are an integral part of these unaudited consolidated financial statements.

9

Table of Contents
Heliogen, Inc.
Consolidated Statements of Cash Flows
($ in thousands)
(Unaudited)
Nine Months Ended
September 30,
20242023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss$(46,322)$(50,797)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
902 1,692 
Impairment charges3,354 1,008 
Provision for inventory reserve1,729  
Share-based compensation
2,676 (6,078)
Change in fair value of warrants
(74)(326)
Change in fair value of contingent consideration 1,289 
Deferred income taxes5 3 
Non-cash operating lease expense1,457 1,261 
Other non-cash operating activities
(47)(1,489)
Changes in assets and liabilities:
Receivables, net
2,747 3,556 
Inventories, net
227 (2,450)
Prepaid and other current assets
(453)(605)
Trade payables and accrued liabilities603 (1,789)
Contract liabilities
2,972 3,056 
Change in contract loss provisions, net(1,069)(1,776)
Other non-current assets and liabilities183 (1,477)
Net cash used in operating activities(31,110)(54,922)
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures
(264)(1,146)
Proceeds from sale of property, plant and equipment847  
Purchases of available-for-sale securities
 (89,856)
Maturities of available-for-sale securities
12,500 161,600 
Net cash provided by investing activities13,083 70,598 
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of stock options
3 1,175 
Proceeds from issuance of common stock under employee stock purchase plan
13 168 
Payment related to taxes for net-share settlement of share-based compensation(73) 
Payment for fractional shares in connection with the reverse stock split (7)
Net cash provided by (used in) financing activities(57)1,336 
Increase (decrease) in cash, cash equivalents and restricted cash(18,084)17,012 
Cash, cash equivalents and restricted cash at the beginning of the period
64,215 47,874 
Cash, cash equivalents and restricted cash at the end of the period
$46,131 $64,886 
The accompanying notes are an integral part of these unaudited consolidated financial statements.

10

Table of Contents
Heliogen, Inc.
Consolidated Statements of Cash Flows (continued)
($ in thousands)
(Unaudited)
Nine Months Ended
September 30,
20242023
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents$44,631 $63,386 
Short-term restricted cash500 500 
Long-term restricted cash1,000 1,000 
Total cash, cash equivalents and restricted cash
$46,131 $64,886 
Non-cash investing and financing activities:
Fair value of Project Warrants and Collaboration Warrants recognized in equity$135 $234 
Capital expenditures incurred but not yet paid
$ $83 
The accompanying notes are an integral part of these unaudited consolidated financial statements.

11

Table of Contents
Heliogen, Inc.
Notes to the Unaudited Consolidated Financial Statements

Note 1—Organization and Basis of Presentation
Background
Heliogen, Inc. and its subsidiaries (collectively, “Heliogen” or the “Company”), is involved in the development and commercialization of next-generation concentrated solar energy. We are developing a modular, artificial intelligence enabled, concentrated solar energy plant that will use an array of mirrors to reflect sunlight and capture, concentrate, store and convert it into cost-effective energy on demand. Unless otherwise indicated or the context requires otherwise, references in our unaudited consolidated financial statements to “we,” “us,” or “our” and similar expressions refer to Heliogen.
Basis of Presentation
The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Accordingly, these unaudited consolidated financial statements do not include all information or notes required by GAAP for annual financial statements. In the opinion of management, the unaudited consolidated financial statements have been prepared on the same basis as the annual financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary for fair statement.
The results reported in these unaudited consolidated financial statements are not necessarily indicative of the results that may be reported for the entire year. These unaudited consolidated financial statements should be read in conjunction with the annual financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (the “SEC”) on March 26, 2024.
Certain immaterial prior period amounts, such as severance costs, have been reclassified to conform to current period presentation. These changes did not have a material impact on our financial position or results of operations.
Liquidity and Going Concern
These financial statements have been prepared assuming the Company will continue as a going concern. This basis of accounting contemplates continuity of operations, realization of assets and satisfaction of liabilities and commitments in the normal course of business. These financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern.
As of September 30, 2024, the Company had liquidity of $44.6 million, consisting of cash and cash equivalents and no debt. During the nine months ended September 30, 2024, the Company incurred a net loss of $46.3 million and used cash in operations of $31.1 million. The Company expects to continue to generate operating losses and have significant cash outflows from operating activities for at least the next few years. Based on these factors, the Company anticipates that it may not have sufficient resources to fund its cash obligations for the next 12 months after the issuance date of the unaudited consolidated financial statements, which raises substantial doubt about the Company’s ability to continue as a going concern.
The Company has evaluated the conditions discussed above and is taking various steps in an effort to alleviate them. The Company is exploring various cost saving opportunities and intends to continue seeking opportunities to generate additional revenue through its commercialization of engineering services. The Company has also engaged a financial advisor and is actively assessing various avenues to secure additional capital, including, but not limited to, the issuance of debt, equity or both. No assurance can be given that any future financing, if needed, will be available or, if available, that it will be on terms that are satisfactory to the Company.

12

Table of Contents
Heliogen, Inc.
Notes to the Unaudited Consolidated Financial Statements
On May 16, 2024, the Company made the strategic decision to implement a targeted plan, which included a workforce reduction, the closing of the Company’s manufacturing facility in Long Beach, California, (the “Manufacturing Facility”) and a reduction in third-party costs. These actions are intended to further reduce structural costs and operating expenses and better align the Company’s operating structure for commercialization with a technology-centric and capital light model, as the Company continues to explore and evaluate strategic alternatives with its third-party financial advisor. Refer to Note 12—Impairment and Other Charges—Manufacturing Facility Closure for additional information.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our unaudited consolidated financial statements and the accompanying notes. Despite our intention to establish accurate estimates and reasonable assumptions, actual results could differ materially from such estimates and assumptions.

Note 2—Revenue
Disaggregated Revenue
The following table provides information about disaggregated revenue:
Three Months EndedNine Months Ended
September 30,September 30,
$ in thousands2024202320242023
Project revenue$420 $950 $1,395 $2,401 
Engineering services revenue14 146 779 473 
Total services revenue434 1,096 2,174 2,874 
Grant revenue616 1,177 2,665 2,730 
Total revenue$1,050 $2,273 $4,839 $5,604 
Services Revenue
Project revenue consists of amounts recognized under contracts with customers for the development, construction and delivery of commercial-scale concentrated solar energy facilities. The Company’s recognized project revenue is associated with a commercial-scale demonstration agreement (“CSDA”) executed with Woodside Energy (USA) Inc. (“Woodside”) in March 2022 for the engineering, procurement and construction of a 5 MWe concentrated solar energy facility to be built in Mojave, California (the “Capella Project”) for the customer’s use in research, development and testing.
Engineering services revenue consists of amounts recognized under contracts with customers for the provision of engineering, research and development (“R&D”), or other similar services in our field of expertise. The Company’s recognized engineering services revenue is associated with engineering studies and projects in the United States (“U.S.”) and Europe.
Grant Revenue
The Company’s grant revenue is primarily related to the Company’s award (the “DOE Award”) from the U.S. Department of Energy (the “DOE”) for costs incurred during such periods that are reimbursable under the DOE Award. During the second quarter of 2024, the proposed budget modification was approved by the DOE for the Capella Project, which did not change the DOE Award amount but resulted in updated cost sharing ratios and indirect rates.

13

Table of Contents
Heliogen, Inc.
Notes to the Unaudited Consolidated Financial Statements
Contract Estimates
In the fourth quarter of 2023, the Company adjusted its Capella Project estimate after completing the front-end engineering design phase. Our current cost estimates for the Capella Project are subject to further refinement as we continue value engineering, exploring additional cost savings opportunities and continue to negotiate an executable engineering, procurement and construction (“EPC”) contract. As a result, the actual cost for the Capella Project could vary from our current estimate.
During the three and nine months ended September 30, 2023, we recognized a reduction in contract loss provisions of $0.5 million and $0.1 million, respectively, associated with our projects in Germany. No provision for contract losses was recognized during the three and nine months ended September 30, 2024.
We amortized $0.5 million and $1.1 million during the three and nine months ended September 30, 2024, respectively, and $0.3 million and $1.6 million during the three and nine months ended September 30, 2023, respectively, of the previously recognized contract loss provisions as a reduction to cost of services revenue incurred during the periods based on percentages of completion.
Performance Obligations
Revenue recognized under contracts with customers, which excludes amounts to be received from government grants, relates solely to the performance obligations satisfied during the three and nine months ended September 30, 2024 and 2023 with no revenue recognized from performance obligations satisfied in prior periods.
As of September 30, 2024, we had approximately $36.8 million of the transaction price allocated to the remaining performance obligation from our contract for the Capella Project. Currently, we are unable to estimate the timing of recognition of revenue for the remaining transaction price.
Receivables
Receivables consisted of the following:
$ in thousandsSeptember 30, 2024December 31, 2023
Trade receivables$790 $954 
Grant receivables:
Billed735  
Unbilled412 3,623 
Total grant receivables1,147 3,623 
Other receivables226 309 
Total receivables
2,163 4,886 
Allowance for credit losses
(209)(207)
Total receivables, net
$1,954 $4,679 

14

Table of Contents
Heliogen, Inc.
Notes to the Unaudited Consolidated Financial Statements
Contract Liabilities
The following table outlines the activity related to contract liabilities:
$ in thousands
Balance as of December 31, 2023
$17,008 
Payments received in advance of performance4,336 
Revenue recognized(1,395)
Recognition of consideration payable associated with Project Warrants(135)
Other 4 
Balance as of September 30, 2024
$19,818 
During the three and nine months ended September 30, 2024, we recognized revenue of $0.4 million and $1.4 million, respectively, that was included in contract liabilities as of December 31, 2023.
Customer Concentrations
The following table shows the customers, including governmental entities, who accounted for greater than 10% of our total revenue:
Three Months EndedNine Months Ended
September 30,September 30,
2024202320242023
Customer A
39 %42 %41 %43 %
Customer B
59 %52 %55 %48 %
The following table shows the customers, including governmental entities, who accounted for greater than 10% of our total receivables:
September 30, 2024December 31, 2023
Customer B59 %77 %
Customer C29 %12 %

Note 3—Warrants
Public Warrants and Private Warrants
The Company’s warrant liabilities as of September 30, 2024 include public warrants (the “Public Warrants”) and private placement warrants (the “Private Warrants,” and together with the Public Warrants, the “Public and Private Warrants”). The Public Warrants and Private Warrants permit warrant holders to purchase in the aggregate 238,095 shares and 6,667 shares, respectively, of the Company’s common stock at an exercise price of $402.50 per share. The Public and Private Warrants became exercisable on March 18, 2022 and expire on December 30, 2026, or earlier upon redemption or liquidation. The Public and Private Warrants are recorded as liabilities on the consolidated balance sheets and measured at fair value at each reporting date, with the change in fair value included in gain (loss) on warrant remeasurement on the consolidated statements of operations.

15

Table of Contents
Heliogen, Inc.
Notes to the Unaudited Consolidated Financial Statements
Project Warrants
In connection with the execution of the CSDA with Woodside in March 2022, the Company issued warrants permitting Woodside to purchase 26,068 shares of the Company’s common stock at an exercise price of $0.35 per share (the “Project Warrants”). The Project Warrants expire upon the earlier of a change in control of the Company or March 28, 2027 and vest pro rata with certain payments required to be made by Woodside under the CSDA. The fair value of the Project Warrants upon issuance was $173.60 per warrant based on the closing price of the Company’s common stock on March 28, 2022, less the exercise price. The Project Warrants are recorded as equity on the consolidated balance sheets.
During the three and nine months ended September 30, 2024, $41 thousand and $0.1 million, respectively, was recognized as additional paid-in capital related to the vesting of Project Warrants. During the three and nine months ended September 30, 2023, $0.1 million and $0.2 million, respectively, was recognized as additional paid-in capital related to the vesting of Project Warrants. As of September 30, 2024, vested Project Warrants were exercisable for 14,978 shares of the Company’s common stock.
Collaboration Warrants
In connection with the execution of a collaboration agreement (the “Collaboration Agreement”) with Woodside in March 2022, the Company issued warrants permitting Woodside to purchase 104,275 shares of the Company’s common stock at an exercise price of $0.35 per share (the “Collaboration Warrants”). Under the Collaboration Agreement, Woodside will assist us in defining product offerings that use our modular technology for potential customers. The Collaboration Warrants expire upon the earlier of a change in control of the Company or March 28, 2027. Of these warrants, (i) half of the warrants vested immediately upon execution of the Collaboration Agreement, to purchase 52,138 shares of the Company’s common stock and (ii) the remaining warrants will vest based on certain specified performance goals under the Collaboration Agreement. The fair value of the Collaboration Warrants upon issuance was $173.60 per warrant based on the closing price of the Company’s common stock on March 28, 2022, less the exercise price.
The Collaboration Warrants are recorded as equity on the consolidated balance sheets and the related expense is recognized ratably as selling, general and administrative (“SG&A”) expense for marketing services to be provided over the estimated service period. The Company recognized SG&A expense, related to the vesting of the Collaboration Warrants, of $0.5 million and $1.5 million, respectively, during the three and nine months ended September 30, 2023, respectively. During the fourth quarter of 2023, we fully impaired the Collaboration Warrants and recognized the remaining expense as an impairment charge on our consolidated statements of operations.

Note 4—Fair Value of Financial Instruments
The Company’s assets and liabilities measured at fair value on a recurring basis are summarized in the following table by fair value measurement level:
$ in thousandsLevelSeptember 30, 2024December 31, 2023
Assets:
Investments1$ $12,386 
Liabilities:
Public Warrants (1)
1$26 $97 
Private Warrants (1)
21 3 
________________
(1)Included in other long-term liabilities on the consolidated balance sheets.

16

Table of Contents
Heliogen, Inc.
Notes to the Unaudited Consolidated Financial Statements
Private Warrants. The fair value of the Private Warrants approximates the fair value of the Public Warrants due to the existence of similar redemption provisions. As a result, the Company has determined that the fair value of the Private Warrants at a specific date would be similar to that of the Public Warrants, and thus the fair value is determined by using the closing price of the Public Warrants, which was $0.003 as of September 30, 2024.
Contingent Consideration. In connection with the acquisition of HelioHeat GmbH in September 2021, part of the fair value of the consideration transferred was contingent consideration. The contingent consideration was classified as Level 3 in the fair value hierarchy and measured at fair value using a probability-weighted discounted cash flow model utilizing estimated timing for the commissioning and required operational period of a commercial facility using the acquired particle receiver technology.
As of September 30, 2024 and December 31, 2023, the fair value of the contingent consideration was zero. The following table summarizes the activities of our Level 3 fair value measurement for the three and nine months ended September 30, 2023:
Three Months EndedNine Months Ended
$ in thousandsSeptember 30, 2023September 30, 2023
Beginning balance$1,590 $353 
Change in fair value (1)
52 1,289 
Ending balance$1,642 $1,642 
________________
(1)The changes in the fair value of the contingent consideration are included in other income, net on our consolidated statements of operations.

Note 5—Inventories
Inventories consisted of the following:
$ in thousandsSeptember 30, 2024December 31, 2023
Raw materials$ $1,870 
Finished goods 2,424 
Work in process 53 
Reserve for excess and obsolete inventory
 (2,391)
Total inventories, net
$ $1,956 
During the second quarter of 2024, we recorded an inventory reserve of $1.7 million, included in cost of services revenue on our consolidated statements of operations, to adjust for excess and obsolete inventories based on our current future project needs.
During the third quarter of 2024, in connection with the closure of our Manufacturing Facility, the Company sold the excess and obsolete inventory and wrote-off the corresponding $4.1 million reserve.


17

Table of Contents
Heliogen, Inc.
Notes to the Unaudited Consolidated Financial Statements
Note 6—Property, Plant & Equipment
Major classes of property, plant and equipment, consisted of the following:
$ in thousandsEstimated Useful Lives in YearsSeptember 30, 2024December 31, 2023
Leasehold improvements
57
$740 $3,107 
Computer equipment
23
2,105 2,165 
Machinery, vehicles and other equipment
57
894 4,307 
Furniture and fixtures
25
538 664 
Construction in progress
 125 
Total property, plant and equipment
4,277 10,368 
Accumulated depreciation
(3,650)(4,791)
Total property, plant and equipment, net
$627 $5,577 
Depreciation expense for property, plant and equipment was $0.1 million and $0.5 million for the three months ended September 30, 2024 and 2023, respectively, and $0.8 million and $1.6 million for the nine months ended September 30, 2024 and 2023, respectively, and is recorded in SG&A expense with a portion allocated to cost of services revenue.
During the second quarter of 2024, we recorded an impairment of property, plant and equipment of $3.4 million, included in impairment and other charges on our consolidated statements of operations. Refer to Note 12—Impairment and Other Charges—Manufacturing Facility Closure for additional information.
Asset Sales
During the second quarter of 2024, we began to sell assets located at our Manufacturing Facility as a result of the decision to close the facility. Refer to Note 1—Organization and Basis of Presentation—Liquidity and Going Concern for additional information. During the three months and nine months ended September 30, 2024, we received $0.4 million and $0.8 million, respectively, in proceeds from the sale of property, plant and equipment and recognized losses of $0.1 million and $0.1 million, respectively, from disposal of assets, which is recorded in SG&A expense.

Note 7—Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consisted of the following:
$ in thousandsSeptember 30, 2024December 31, 2023
Payroll and other employee benefits
$588 $1,084 
Professional fees
1,126 1,913 
Research, development and project costs
4,892 3,658 
Inventory in-transit 29 
Operating lease liabilities, current portion
2,387 1,792 
Other accrued expenses
802 431 
Total accrued expenses and other current liabilities
$9,795 $8,907 


18

Table of Contents
Heliogen, Inc.
Notes to the Unaudited Consolidated Financial Statements
Note 8—Leases
The Company has operating leases, primarily for real estate. There are no material residual value guarantees associated with any of the Company’s operating leases.
As discussed in Note 1—Organization and Basis of Presentation—Liquidity and Going Concern, on May 16, 2024, the Company made the decision to implement a targeted plan, which included a workforce reduction, the closing of its Manufacturing Facility and a reduction in third-party costs. Due to the decision to close the Manufacturing Facility, the Company no longer anticipates utilizing the five-year renewal option for the manufacturing space in Long Beach, California (the “Long Beach Lease”). As a result, during the nine months ended September 30, 2024, our right-of-use asset and operating lease liabilities for the Long Beach Lease were both decreased by $6.4 million. As of September 30, 2024, the Company still has a $1.5 million standby letter of credit outstanding associated with the Long Beach lease, included in restricted cash on the consolidated balance sheet. No amounts have been drawn under the standby letter of credit.
The following table provides information on the amounts of our right-of-use assets and liabilities included on our consolidated balances sheets:
$ in thousandsFinancial Statement LineSeptember 30, 2024December 31, 2023
Operating lease right-of-use assets
Operating lease right-of-use assets
$6,166 $13,909 
Operating lease liabilities, current
Accrued expenses and other current liabilities2,387 1,792 
Operating lease liabilities, non-current
Operating lease liabilities, non-current
4,531 12,878 
The following table summarizes the components of lease costs:
Three Months EndedNine Months Ended
September 30,September 30,
$ in thousands2024202320242023
Operating lease cost
$676 $688 $2,079 $2,040 
Sublease income(43)(45)(125)(114)
Total lease cost
$633 $643 $1,954 $1,926 
The Company has variable and other related lease costs which were not considered material for the three and nine months ended September 30, 2024 and 2023.
The weighted-average remaining lease terms and discount rates for the Company’s operating leases were as follows:
September 30, 2024December 31, 2023
Weighted-average remaining lease term (years)
3.27.0
Weighted-average discount rate7.9 %7.4 %
The following table summarizes the supplemental cash flow information related to leases:
Nine Months Ended
September 30,
$ in thousands
20242023
Cash paid for amounts included in the measurement of operating lease liabilities
$2,089 $2,003 
Right-of-use assets obtained in exchange for new operating lease liabilities
132 187 
Decrease in right-of-use asset and operating lease liabilities due to lease remeasurement
6,417  

19

Table of Contents
Heliogen, Inc.
Notes to the Unaudited Consolidated Financial Statements
As of September 30, 2024, the maturities of our future undiscounted cash flows associated with our operating lease liabilities were as follows:
$ in thousands
2024 (remaining months)$730 
20252,854 
20262,372 
2027967 
2028539 
Thereafter
549 
Total future lease payments$8,011 
Less: Imputed interest
(1,093)
Present value of future lease payments$6,918 

Note 9—Equity
Stockholder Matters
As previously reported, on November 7, 2023, the NYSE notified the Company that it had determined to commence proceedings to delist the Company’s common stock and Public Warrants from the NYSE. Trading in these securities was immediately suspended. The NYSE reached its decision to delist these securities pursuant to Section 802.01B of the NYSE Listed Company Manual. On April 15, 2024, the Company notified the NYSE that the Company intended to withdraw its appeal of the delisting determination and on June 10, 2024, the NYSE filed with the SEC a Notification of Removal From Listing and/or Registration under Section 12(b) of the Exchange Act on Form 25 in order to delist the Company’s common stock and Public Warrants from the NYSE and deregister the Company’s common stock and Public Warrants under Section 12(b) of the Exchange Act. The delisting became effective on June 20, 2024.
The Company’s common stock is currently quoted on the OTCQX, the highest market tier operated by the OTC Markets Group, Inc. The Company intends to continue to comply with public company SEC regulations and other NYSE listing requirements, including filing quarterly financial statements, having independently audited financials, and maintaining an independent board of directors with corporate governance rules and oversight committees.
Stockholders Rights Plan
On April 16, 2023, the Company’s Board of Directors (the “Board”) declared a dividend of one preferred share purchase right (“Right”) for each outstanding share of the Company’s common stock to the stockholders of record as of the close of business on April 28, 2023, and adopted a limited duration stockholder rights plan, as set forth in the Rights Agreement, dated as of April 16, 2023 (the “Rights Agreement”), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent. The Rights will be exercisable only if a person or group (an “acquiring person”) acquires or launches a tender or exchange offer to acquire beneficial ownership (which includes certain synthetic equity interests) of 12.5% or more of the Company’s outstanding common stock (20% for certain passive institutional investors as described in the Rights Agreement) without the approval of the Board. Under the original terms of the Rights Agreement, once the Rights become exercisable, each Right will entitle its holder (other than the acquiring person, whose rights will become void) to purchase for $122.50, subject to adjustment, additional shares of our common stock having a market value of twice such exercise price. In addition, the Rights Agreement has customary flip-over and exchange features.

20

Table of Contents
Heliogen, Inc.
Notes to the Unaudited Consolidated Financial Statements
On April 16, 2024, we entered into Amendment No. 1 (the “Amendment”) to the Rights Agreement. The Amendment extends the final expiration date of the Rights Agreement by one year such that the Rights will now expire on April 17, 2025. The Amendment also changes the definition of “Exercise Price” from $122.50 to $26.40 and amends the definition of “acquiring person” to reflect the terms and conditions of the limited waiver previously granted by us to Nant Capital, LLC and certain of its affiliates, as previously disclosed on the Company’s Current Report on Form 8-K dated February 15, 2024. The Rights Agreement otherwise remains unmodified and in full force and effect in accordance with its terms.
The Rights Agreement will reduce the likelihood that any entity, person or group gains control of Heliogen through open market accumulation without paying all stockholders an appropriate control premium or without providing our Board sufficient time to make informed judgments and take actions that are in the best interests of all stockholders.

Note 10—Loss per Share
Basic and diluted losses per share (“EPS”) were as follows:
Three Months EndedNine Months Ended
September 30,September 30,
$ in thousands, except share and per share data2024202320242023
Numerator:
Net loss$(11,815)$(18,570)$(46,322)$(50,797)
Denominator:
Weighted-average common shares outstanding6,016,299 5,865,954 5,981,790 5,698,405 
Weighted-average impact of warrants (1)
70,083 69,869 69,239 66,951 
Denominator for basic EPS – weighted-average shares
6,086,382 5,935,823 6,051,029 5,765,356 
Effect of dilutive securities
    
Denominator for diluted EPS – weighted-average shares
6,086,382 5,935,823 6,051,029 5,765,356 
EPS – Basic and Diluted
$(1.94)$(3.13)$(7.66)$(8.81)
________________
(1)Warrants that have a $0.35 exercise price per common share are assumed to be exercised when vested because common shares issued for little consideration upon exercise are included in outstanding shares for the purposes of computing basic and diluted EPS.
The following securities were excluded from the calculation of losses per share as their impact would be anti-dilutive:
Three Months EndedNine Months Ended
September 30,September 30,
2024202320242023
Stock options172,453 239,424 172,453 239,424 
Shares issuable under the employee stock purchase plan17,571 18,103 17,571 18,103 
Unvested restricted stock units570,521 447,286 570,521 447,286 
Unvested warrants63,227 61,533 63,227 61,533 
Vested warrants244,762 244,762 244,762 244,762 


21

Table of Contents
Heliogen, Inc.
Notes to the Unaudited Consolidated Financial Statements
Note 11—Share-based Compensation
The Heliogen, Inc. 2021 Equity Incentive Plan aims to incentivize employees, directors and consultants who render services to the Company through the granting of stock awards, including stock options, stock appreciation right awards, restricted stock awards, restricted stock unit (“RSU”) awards, performance awards, and other stock-based awards.
The following table summarizes our share-based compensation expense by the affected line on our consolidated statements of operations:
Three Months EndedNine Months Ended
September 30,September 30,
$ in thousands2024202320242023
Cost of services revenue$44 $197 $152 $442 
Selling, general and administrative
826 199 2,497 (7,344)
Research and development
(161)(91)27 824 
Total share-based compensation expense
$709 $305 $2,676 $(6,078)
The following table summarizes our share-based compensation expense by grant type:
Three Months EndedNine Months Ended
September 30,September 30,
$ in thousands2024202320242023
Stock options$107 $172 $353 $(11,883)
Restricted stock units
590 75 2,293 5,449 
Employee stock purchase plan12 49 30 240 
Vendor Warrants
 9  116 
Total share-based compensation expense
$709 $305 $2,676 $(6,078)
Stock Options
The following table summarizes the Company’s stock option activity:
$ in thousands, except share and per share dataNumber of SharesWeighted Average Exercise Price ($)Weighted Average Remaining Contractual Life (Years)Aggregate Intrinsic Value ($)
Outstanding balance as of December 31, 2023
204,394 $12.64 5.82$6 
Exercised(3,818)0.70 
Forfeited(3,985)53.95 
Expired(24,138)30.13 
Outstanding balance as of September 30, 2024
172,453 $9.50 4.03$1 
Exercisable as of September 30, 2024
162,696 $9.12 3.89$1 
As of September 30, 2024, the unrecognized compensation cost related to stock options was $0.2 million which is expected to be recognized over a weighted-average period of 0.5 years.

22

Table of Contents
Heliogen, Inc.
Notes to the Unaudited Consolidated Financial Statements
Restricted Stock Units
The following table summarizes the Company’s RSU award activity:
Number of SharesWeighted Average Grant Date Fair Value ($)
Unvested as of December 31, 2023
339,287 $58.92 
Granted523,702 1.54 
Vested(129,505)42.92 
Forfeited(162,963)38.24 
Unvested as of September 30, 2024
570,521 $15.58 
As of September 30, 2024, the unrecognized compensation cost related to unvested RSU awards was $4.4 million which is expected to be recognized over a weighted-average period of 2.1 years.

Note 12—Impairment and Other Charges
Impairment and other charges consisted of the following:
Three Months EndedNine Months Ended
September 30,September 30,
$ in thousands2024202320242023
Property, plant and equipment
$ $ $3,354 $ 
Goodwill
   1,008 
Severance costs202 115 847 587 
Manufacturing Facility closing costs  161  
Total impairment and other charges
$202 $115 $4,362 $1,595 
Manufacturing Facility Closure
As discussed in Note 1—Organization and Basis of Presentation—Liquidity and Going Concern, on May 16, 2024, the Company made the strategic decision to implement a targeted plan, which included a workforce reduction, the closing of its Manufacturing Facility and a reduction in third-party costs. Costs and charges related to the implementation of the Company’s targeted plan, are accrued when probable and reasonably estimable or at the time of program announcement. The Company expects to incur the costs associated with its targeted plan over the remainder of 2024 and possibly into the first quarter of 2025, however the ultimate amount and timing of total costs and charges in connection with the Company’s targeted plan may vary due to a variety of factors, including the finalization of the closure of the Manufacturing Facility and continued sales of property, plant and equipment located at the Manufacturing Facility.
During the second quarter of 2024, management concluded that these actions constituted a triggering event and as a result, we performed an impairment assessment for our long-lived assets, including right-of-use assets. During the second quarter of 2024, we recorded impairments of $3.4 million to property, plant and equipment related to leasehold improvements, machinery and equipment and other fixed assets located at our Manufacturing Facility.
During the second quarter of 2024, we recorded severance costs of $0.6 million related to employee transition, severance and related benefits, primarily associated with the workforce reduction mentioned above.

23

Table of Contents
Heliogen, Inc.
Notes to the Unaudited Consolidated Financial Statements
During the second quarter of 2024, we recorded reorganization costs of $0.2 million associated with closing our Manufacturing Facility. We estimate that we could incur between $0.2 million to $2.0 million of costs associated with closing the Manufacturing Facility, including lease termination costs and other related costs, over the remainder of 2024 and possibly into the first quarter of 2025.
As of September 30, 2024, the reorganization costs liability decreased to $0.1 million due to payments made during the three months ended September 30, 2024, associated with closing our Manufacturing Facility. The reorganization costs liability is included in accrued expenses and other current liabilities on our consolidated balance sheets.
Goodwill Impairment
During the first quarter of 2023, we assessed our goodwill for impairment due to a sustained decrease in the Company’s market capitalization. The Company concluded that it was more likely than not that the fair value of its reporting unit was less than its carrying amount as of March 31, 2023. As a result, we fully impaired goodwill and recorded an impairment of $1.0 million during the first quarter of 2023.
Reorganization Costs
During the three months ended September 30, 2024, we recorded additional severance costs of $0.2 million related to employee severance and related benefits. In October 2024, we initiated additional workforce reductions which resulted in severance costs of approximately $0.6 million for employee severance and related benefits.
In February 2023, the Company initiated a strategic plan to respond to market feedback, streamline our operations, and improve our financial condition. As a result, during the three and nine months ended September 30, 2023, we recorded severance costs of $0.1 million and $0.6 million, respectively, for employee severance and related benefits.

Note 13—Income Taxes
We calculate our quarterly tax provision pursuant to the guidelines in Accounting Standards Codification (“ASC”) 740, Income Taxes. ASC 740 requires companies to estimate the annual effective tax rate for current year ordinary income. The estimated annual effective tax rate represents the Company’s estimate of the tax provision in relation to the best estimate of pre-tax ordinary income or loss. The estimated annual effective tax rate is then applied to year-to-date ordinary income or loss to calculate the year-to-date interim tax provision. The relationship between our income tax provision or benefit and our pre-tax book income or loss can vary significantly from period to period considering, among other factors, the overall level of pre-tax book income or loss and changes in the blend of jurisdictional income or loss that is taxed at different rates and changes in valuation allowances. The income tax provision was $1 thousand and $5 thousand for the three and nine months ended September 30, 2024, respectively. The income tax provision was $1 thousand and $3 thousand for the three and nine months ended September 30, 2023, respectively. Any income tax benefit associated with the pre-tax loss for the three and nine months ended September 30, 2024 and 2023, resulting primarily from the U.S. jurisdiction, is offset by a full valuation allowance.
The Company is under audit by the Internal Revenue Services for the year ended December 31, 2022. We believe that we have made adequate provision for all income tax uncertainties.


24

Table of Contents
Heliogen, Inc.
Notes to the Unaudited Consolidated Financial Statements
Note 14—Related Party Transactions
NantG Power, LLC
On March 24, 2023, Heliogen entered into an agreement with NantG Power, LLC (“NantG”), an affiliated sister-company to Nant Capital LLC, a holder of more than 5% of Heliogen’s outstanding voting stock, to provide front-end concept design and R&D engineering services. During the three and nine months ended September 30, 2024, the Company recognized $20 thousand and $0.2 million, respectively, of services revenue from NantG. During the three and nine months ended September 30, 2023, the Company recognized $15 thousand of services revenue from NantG. As of September 30, 2024 and December 31, 2023, we had outstanding accounts receivable of $20 thousand and $0.1 million, respectively, with NantG.

Note 15—Commitments and Contingencies
From time to time, we are involved in various claims and lawsuits arising in the normal course of business, including proceedings involving tort and other general liability claims and other miscellaneous claims. We recognize a liability when we believe the loss is probable and reasonably estimable. We currently believe that the ultimate outcome of such lawsuits and proceedings will not, individually or in the aggregate, have a material effect on our unaudited consolidated financial statements as of and for the nine months ended September 30, 2024.


25

Table of Contents
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
The following management’s discussion and analysis (“MD&A”) provides information that management believes is relevant to an assessment and understanding of our consolidated results of operations and financial condition. The following discussion includes forward-looking statements that involve risks, uncertainties and assumptions, including those described in “Cautionary Note Regarding Forward-Looking Statements” included in the fore-part in this Quarterly Report on Form 10-Q (our “Quarterly Report”) and included in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2023 (our “Annual Report”), as filed with the SEC on March 26, 2024.
The following MD&A should be read in conjunction with our unaudited consolidated financial statements and related notes included in Part I Item 1 in this Quarterly Report and our audited consolidated financial statements as of December 31, 2023, included in our Annual Report.
Overview
Heliogen, Inc. and its subsidiaries (collectively, “Heliogen,” the “Company,” “we,” “us,” or “our”) is a leader in next generation concentrated solar energy. We are developing a modular, artificial intelligence enabled, concentrated solar energy plant that uses an array of mirrors to reflect sunlight and capture, concentrate, store and convert it into cost-effective energy on demand. Our product offering will deliver industrial process steam or power, dispatchable around the clock using thermal energy storage based on proven technology. Our next-generation system will be able to cost-effectively generate and store thermal energy at very high temperatures, enabling more cost-effective production of electricity at a smaller scale. The inclusion of a thermal energy storage system distinguishes our solution from clean energy provided by typical photovoltaic and wind installations which do not produce thermal energy and are only able to produce energy intermittently unless battery storage is added. The system will be configurable for several applications, including carbon-free industrial-grade heat and steam (for use in industrial processes), and clean power (electricity) for a variety of applications, based on a customer’s needs.
Recent Developments
In May 2024, we implemented a targeted plan, which included a workforce reduction, the closing of our manufacturing facility in Long Beach, California, (the “Manufacturing Facility”) and a reduction in third-party costs. These actions are intended to further reduce structural costs and operating expenses and better align our operating structure for commercialization with a technology-centric and capital light model, as we continue to explore and evaluate strategic alternatives with our third-party financial advisor.
We estimate that we could incur the following charges in connection with the targeted plan; $0.2 million to $2.0 million of costs associated with closing the manufacturing facility, including lease termination costs and other related costs, in addition to the $3.4 million of asset impairment charges and $0.6 million of employee transition, severance payments and related benefits that were incurred during the second quarter of 2024. We have incurred $4.2 million of these costs during the nine months ended September 30, 2024, which were recorded as impairment and other charges on our consolidated statements of operations. We expect to incur the remainder of these costs through the end of 2024 and possibly into the first quarter of 2025. Refer to Note 12—Impairment and Other Charges—Manufacturing Facility Closure for additional information.
How We Generate Revenue
We primarily generate revenue by contracting with owner-operators to build turnkey facilities that deploy Heliogen’s technology. Our services revenue which is derived from customer contracts, is primarily recognized over time using the incurred costs method for our contracts with customers that include projects under development and engineering and design services. Engineering service contracts can be short-term or span several years and we recognize revenue over time as customers receive and consume the benefit of such services. Additionally, we have government grants which are accounted for as grant revenue and are recognized only when there is reasonable assurance that the entity will comply with any conditions attached to the grant and the grant funds will be received.

26

Table of Contents
Cost of Conducting Our Business
Cost of revenue consists primarily of direct material, labor and subcontractor costs related to our revenue contracts. Additionally, we have indirect costs related to contract performance, such as indirect labor, supplies, tools and allocated depreciation.
Results of Operations
Comparison of the Three Months Ended September 30, 2024 and 2023
Three Months Ended
September 30,
$ in thousands20242023$ Change% Change
Revenue:
Services revenue$434 $1,096 $(662)(60)%
Grant revenue616 1,177 (561)(48)%
Total revenue1,050 2,273 (1,223)
Cost of revenue:
Cost of services revenue (including depreciation)494 1,220 (726)(60)%
Cost of grant revenue616 1,177 (561)(48)%
Contract loss (adjustments) provisions— (538)538 (100)%
Gross profit (loss)(60)414 (474)
Operating expenses:
Selling, general and administrative7,854 14,882 (7,028)(47)%
Research and development4,509 5,162 (653)(13)%
Impairment and other charges202 115 87 76 %
Operating loss(12,625)(19,745)7,120 
Interest income, net535 335 200 60 %
Gain on warrant remeasurement53 74 (21)(28)%
Other income, net223 767 (544)(71)%
Net loss before taxes(11,814)(18,569)6,755 
Provision for income taxes(1)(1)— — %
Net loss$(11,815)$(18,570)$6,755 
Revenue and Gross Loss
During the three months ended September 30, 2024, we recognized total revenue of $1.1 million, a decrease of $1.2 million compared to total revenue of $2.3 million for the three months ended September 30, 2023.
We recognized services revenue of $0.4 million during the three months ended September 30, 2024, a decrease of $0.7 million compared to services revenue of $1.1 million for the three months ended September 30, 2023. The decrease in services revenue is primarily due to a reduction in revenue recognized on the engineering, procurement and construction of a 5 MWe concentrated solar energy facility to be built in Mojave, California (the “Capella Project”) during the three months ended September 30, 2024 compared to the three months ended September 30, 2023, resulting from a decrease in the cost incurred on the project.
We recognized grant revenue of $0.6 million during the three months ended September 30, 2024, a decrease of $0.6 million compared to grant revenue of $1.2 million for the three months ended September 30, 2023. The decrease was driven by a decrease in reimbursable costs incurred on the Capella Project under the award (the “DOE Award”) received from the U.S. Department of Energy (the “DOE”) for the three months ended September 30, 2024.

27

Table of Contents
During the three months ended September 30, 2024, we recognized a gross loss of $0.1 million, a change of $0.5 million compared to gross profit of $0.4 million for the three months ended September 30, 2023. The change was primarily driven by the recognition of a reduction in our contract loss provision during the three months ended September 30, 2023 of $0.5 million associated with our projects in Germany.
Selling, General and Administrative
The following table summarizes selling, general and administrative (“SG&A”) expenses:
Three Months Ended
September 30,
$ in thousands20242023$ Change
Employee compensation, excluding share-based compensation$2,853 $5,606 $(2,753)
Share-based compensation826 199 627 
Collaboration Warrants— 496 (496)
Other selling, general and administrative4,175 8,581 (4,406)
Total selling, general and administrative$7,854 $14,882 $(7,028)
During the three months ended September 30, 2024, we recognized SG&A expense of $7.9 million, a decrease of $7.0 million compared to SG&A expense of $14.9 million for the three months ended September 30, 2023. The decrease was primarily driven by a decrease of $2.9 million in professional and consulting fees as we focused on reducing third-party costs, a decrease of $2.8 million in employee compensation primarily driven by headcount reductions and a decrease of $1.2 million in other SG&A expense as we focused on reducing discretionary spending.
Research and Development
The following table summarizes research and development (“R&D”) expenses:
Three Months Ended
September 30,
$ in thousands20242023$ Change
Employee compensation, excluding share-based compensation$1,966 $3,653 $(1,687)
Share-based compensation(161)(91)(70)
Other research and development2,704 1,600 1,104 
Total research and development$4,509 $5,162 $(653)
During the three months ended September 30, 2024, we recognized R&D expense of $4.5 million, a decrease of $0.7 million compared to R&D expense of $5.2 million for the three months ended September 30, 2023. The decrease was primarily driven by a decrease of $1.7 million in employee compensation primarily due to headcount reductions, partially offset by an increase in other R&D costs associated with the construction of our steam plant, located in Plains, Texas (the “Texas Steam Plant”).
Other Income, Net
During the three months ended September 30, 2024, we recognized other income of $0.2 million, a decrease of $0.5 million compared to other income of $0.8 million for the three months ended September 30, 2023. The decrease is primarily attributable to a decrease of $0.8 million in accretion income related to our investments in available-for-sale securities, which was partially offset by a cash prize award of $0.2 million received for our heliostats during the three months ended September 30, 2024.

28

Table of Contents
Comparison of the Nine Months Ended September 30, 2024 and 2023
Nine Months Ended
September 30,
$ in thousands20242023$ Change% Change
Revenue:
Services revenue$2,174 $2,874 $(700)(24)%
Grant revenue2,665 2,730 (65)(2)%
Total revenue4,839 5,604 (765)
Cost of revenue:
Cost of services revenue (including depreciation)3,851 3,221 630 20 %
Cost of grant revenue2,665 2,690 (25)(1)%
Contract loss (adjustments) provisions— (148)148 (100)%
Gross profit (loss)(1,677)(159)(1,518)
Operating expenses:
Selling, general and administrative29,714 36,227 (6,513)(18)%
Research and development13,051 15,368 (2,317)(15)%
Impairment and other charges4,362 1,595 2,767 173 %
Operating loss(48,804)(53,349)4,545 
Interest income, net1,893 888 1,005 113 %
Gain on warrant remeasurement74 326 (252)(77)%
Other income, net520 1,341 (821)(61)%
Net loss before taxes(46,317)(50,794)4,477 
Provision for income taxes(5)(3)(2)67 %
Net loss$(46,322)$(50,797)$4,475 
Revenue and Gross Loss
During the nine months ended September 30, 2024, we recognized total revenue of $4.8 million, a decrease of $0.8 million compared to total revenue of $5.6 million for the nine months ended September 30, 2023.
We recognized services revenue of $2.2 million during the nine months ended September 30, 2024, a decrease of $0.7 million compared to services revenue of $2.9 million for the nine months ended September 30, 2023. The decrease in services revenue is primarily due to a reduction in revenue recognized on the Capella Project during the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023, resulting from a decrease in the cost incurred on the project, which was partially offset by an increase in engineering services performed during the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023.
We recognized grant revenue of $2.7 million during the nine months ended September 30, 2024, a decrease of $0.1 million compared to grant revenue of $2.7 million for the nine months ended September 30, 2023. The decrease was driven by a decrease in reimbursable costs incurred on the Capella Project under the DOE Award, which was partially offset by the approval of the proposed budget modification by the DOE for the Capella Project, which did not change the DOE Award amount but resulted in more favorable cost sharing ratios and indirect rates for the nine months ended September 30, 2024.
During the nine months ended September 30, 2024, we recognized a gross loss of $1.7 million, a change of $1.5 million compared to gross loss of $0.2 million for the nine months ended September 30, 2023. The change was primarily driven by an inventory reserve of $1.7 million recorded during the nine months ended September 30, 2024 to adjust for excess and obsolete inventories based on our current future project needs. The decrease was partially offset by the recognition of a contract loss provision during the nine months ended September 30, 2023 of $0.1 million primarily related to our German operations.

29

Table of Contents
Selling, General and Administrative
The following table summarizes SG&A expenses:
Nine Months Ended
September 30,
$ in thousands20242023$ Change
Employee compensation, excluding share-based compensation$10,374 $16,365 $(5,991)
Share-based compensation2,497 (7,344)9,841 
Collaboration Warrants— 1,486 (1,486)
Other selling, general and administrative16,843 25,720 (8,877)
Total selling, general and administrative$29,714 $36,227 $(6,513)
During the nine months ended September 30, 2024, we recognized SG&A expense of $29.7 million, a decrease of $6.5 million compared to SG&A expense of $36.2 million for the nine months ended September 30, 2023. The decrease was primarily driven by a decrease of $6.5 million in professional and consulting fees as we focused on reducing third-party costs, a decrease of $6.0 million in employee compensation primarily driven by headcount reductions, a decrease of $1.5 million in Collaboration Warrants because they were fully impaired in the fourth quarter of 2023 and a decrease of $1.6 million in other SG&A expense as we focused on reducing discretionary spending. The decrease was partially offset by a $9.8 million increase in share-based compensation primarily due to a one-time reversal of share-based compensation of $12.5 million during the first quarter of 2023, as a result of stock options forfeited in connection with the termination of our former Chief Executive Officer.
Research and Development
The following table summarizes R&D expenses:
Nine Months Ended
September 30,
$ in thousands20242023$ Change
Employee compensation, excluding share-based compensation$6,972 $10,425 $(3,453)
Share-based compensation27 824 (797)
Other research and development6,052 4,119 1,933 
Total research and development$13,051 $15,368 $(2,317)
During the nine months ended September 30, 2024, we recognized R&D expense of $13.1 million, a decrease of $2.3 million compared to R&D expense of $15.4 million for the nine months ended September 30, 2023. The decrease was driven by a decrease of $3.5 million in employee compensation primarily due to headcount reductions and a decrease of $0.8 million in share-based compensation expense due to forfeitures, partially offset by an increase in other R&D costs associated with the construction of our Texas Steam Plant.
Impairment and Other Charges
During the nine months ended September 30, 2024, we recognized impairment and other charges of $4.4 million, consisting of $3.4 million to property, plant and equipment related to leasehold improvements, machinery and equipment and other fixed assets located at our Manufacturing Facility, $0.8 million of employee severance and related benefits associated with workforce reductions and $0.2 million of reorganization costs associated with closing our Manufacturing Facility. Refer to Note 12—Impairment and Other Charges for additional information.
During the nine months ended September 30, 2023, we recognized impairment and other charges of $1.6 million, consisting of an impairment charge of $1.0 million to fully impair goodwill due to a sustained decrease in our market capitalization and $0.6 million expense for employee severance and related benefits.

30

Table of Contents
Interest Income, Net
During the nine months ended September 30, 2024, we recognized interest income of $1.9 million, an increase of $1.0 million compared to interest income of $0.9 million for the nine months ended September 30, 2023. The increase is primarily attributable to the rising interest rate environment for our investments, partially offset by the decrease in our average investment balance.
Other Income, Net
During the nine months ended September 30, 2024, we recognized other income of $0.5 million, a decrease of $0.8 million compared to other income of $1.3 million for the nine months ended September 30, 2023. The decrease is primarily attributable to a decrease of $2.5 million in accretion income related to our investments in available-for-sale securities, partially offset by a gain of $1.3 million for the nine months ended September 30, 2023 in the estimated fair value of the contingent consideration associated with the acquisition of HelioHeat GmbH based on the revised probability of payment, which was partially offset by a cash prize award of $0.2 million received for our heliostats during the nine months ended September 30, 2024.
Liquidity and Capital Resources
Our principal sources of liquidity are cash and investments on hand, which are short-term in duration and highly liquid, and cash receipts from customers and government grants. Our principal uses of cash are expenditures related to project development and completion, as well as R&D and SG&A expenditures in support of our technology development and operational support.
As of September 30, 2024, the Company had liquidity of $44.6 million, consisting of cash and cash equivalents and no debt. As of November 4, 2024, the Company had liquidity of $40.7 million, consisting of cash and cash equivalents and no debt.
Going Concern
The accompanying financial statements have been prepared assuming we will continue as a going concern. As of September 30, 2024, our liquidity was $44.6 million and we had an accumulated deficit of $484.5 million. During the nine months ended September 30, 2024, we incurred a net loss of $46.3 million and used cash in operations of $31.1 million. We expect to continue to generate operating losses and have significant cash outflows from operating activities for at least the next few years. Based on our liquidity position as of September 30, 2024 and our current forecast of operating results and cash flows, we anticipate that we may not have sufficient resources to fund our cash obligations for the next 12 months after the issuance date of this Quarterly Report. These factors raise substantial doubt about our ability to continue as a going concern.
We have evaluated the conditions discussed above and we are taking various steps in an effort to alleviate them. We are exploring various cost saving opportunities and intend to continue seeking opportunities to generate additional revenue through our commercialization of engineering services. We have also engaged a financial advisor and we are actively assessing various avenues to secure additional capital, including, but not limited to, the issuance of debt, equity or both. No assurance can be given that any future financing, if needed, will be available or, if available, that it will be on terms that are satisfactory to us. If we are unable to effectively implement additional cost reductions, generate additional revenue or raise additional funding, we may be forced to delay, reduce or eliminate some or all of our commercialization efforts, product expansion or R&D programs and our business, financial condition and results of operations could be materially and adversely affected. Assuming no additional funding and based on our current operating and development plans, we expect that existing liquidity as of the date of this filing will be sufficient to fund currently anticipated operating expenses into the second half of 2025.
On May 16, 2024, the Company made the strategic decision to implement a targeted plan, which included a workforce reduction, the closing of the Manufacturing Facility, and a reduction in third-party costs. These actions are intended to further reduce structural costs and operating expenses and better align the Company’s operating structure for commercialization with a technology-centric and capital light model, as the Company continues to explore and evaluate strategic alternatives with its third-party financial advisor.

31

Table of Contents
Summary of Cash Flows
The following table provides a summary of our cash flows:
Nine Months Ended
September 30,
$ in thousands20242023
Net cash used in operating activities$(31,110)$(54,922)
Net cash provided by investing activities13,083 70,598 
Net cash provided by (used in) financing activities(57)1,336 
Net Cash from Operating Activities. Net cash used in operating activities was $31.1 million for the nine months ended September 30, 2024 compared to net cash used in operating activities of $54.9 million for the nine months ended September 30, 2023. The $23.8 million decrease in the net cash used in operating activities was primarily driven by reductions in headcount and discretionary spending as we focused on cost saving opportunities.
Net Cash from Investing Activities. Net cash provided by investing activities was $13.1 million for the nine months ended September 30, 2024 compared to net cash provided by investing activities of $70.6 million for the nine months ended September 30, 2023. For the nine months ended September 30, 2024, we received proceeds from the maturities of available-for-sale securities of $12.5 million to fund our operations and proceeds from the sale of property, plant and equipment of $0.8 million, partially offset by capital expenditures of $0.3 million. For the nine months ended September 30, 2023, we received net proceeds from the maturities of available-for-sale securities of $71.7 million, partially offset by capital expenditures of $1.1 million.
Net Cash from Financing Activities. Net cash used in financing activities was $57 thousand for the nine months ended September 30, 2024 compared to net cash provided by financing activities of $1.3 million for the nine months ended September 30, 2023. For the nine months ended September 30, 2024, we paid $73 thousand related to taxes for net-share settlement of share-based compensation, partially offset by proceeds of $13 thousand associated with our employee stock purchase plan. For nine months ended September 30, 2023, we received proceeds of $1.2 million from stock option exercises and proceeds of $0.2 million associated with our employee stock purchase plan.
Cash Requirements
Our material cash requirements from known contractual and other obligations consist of our long-term operating leases, which are primarily for real estate. Refer to Note 8—Leases for additional information regarding maturity analysis of our operating leases.
Critical Accounting Estimates
There have been no material changes to our discussion of critical accounting estimates from those set forth in our Annual Report.

Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are a smaller reporting company as defined by Item 10 of Regulation S-K and are not required to provide the information otherwise required under this item.


32

Table of Contents
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, and as a result of the material weaknesses in our internal control over financial reporting described in our Annual Report, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2024, our disclosure controls and procedures were not effective.
Changes in Internal Control over Financial Reporting
Other than executing upon the implementation of the remediation measures described in our Annual Report and the associated changes to our internal control over financial reporting, there were no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

33

Table of Contents
Part II - Other Information
Item 1. Legal Proceedings
关于各种承诺和或有事项的信息在本季度报告第一部分第1项的未审计合并基本报表的第15条——承诺和或有事项中进行了描述。

第1A项。风险因素
与我们年度报告第一部分第1A项中先前披露的风险因素相比,没有重大变化,补充了我们季度报告第二部分第IA项中先前披露的风险因素,适用于截至2024年3月31日和2024年6月30日的每个时期。

项目二。未注册的股权销售和款项使用
无。

第3项。对优先证券的违约
无。

第4项。矿山安全披露。
无。

项目5. 其他资讯
没有

34

目录
项目6. 附件
展品编号描述参照所述公司章程
形式文件编号附件申报日期
3.18-K001-402093.12022年1月6日
3.28-K001-402093.12023年8月31日
3.310-Q001-402093.22022年11月8日
3.48-K001-402093.12023年4月17日
4.18-K001-402094.12023年4月17日
4.28-K001-402094.1,包括附注99.1,我们的报告在2024年4月16日提交的6-k表格
31.1*
31.2*
32.1**
32.2**
101
我们截至2024年9月30日的季度报告(10-Q)中的以下信息,采用iXBRL(内联可扩展业务报告语言)格式:(i)合并资产负债表,(ii)合并损益表,(iii)合并全面损失表,(iv)合并股东权益表,(v)合并现金流量表,以及(vi)未经审计的合并基本报表附注。
104封面互动数据文件(以内嵌XBRL格式且包含于展示文件101中)。
________________
* 附带提交。
备有如下物品。
35

目录
签名
根据1934年证券交易法的规定,注册人已正式授权下述签署本报告,并于2024年11月8日正式签署。

赫利根公司
作者:/s/ 克里斯蒂安娜·奥比亚亚
克里斯蒂安娜·奥比亚亚
首席执行官
(首席执行官)
作者:
/s/ 菲尔普斯·莫里斯
菲尔普斯·莫里斯
财务长
(信安金融财务主管)
.

36